Ascendis Pharma has filed a patent for hydrogel prodrug compositions using cross-linked hyaluronic acid with a drug-linker capable of releasing the drug under physiological conditions. The invention also includes methods for preparing the compositions and treating ocular conditions. GlobalData’s report on Ascendis Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ascendis Pharma AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ascendis Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Ascendis Pharma's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Ocular drug delivery system using cross-linked ha

Source: United States Patent and Trademark Office (USPTO). Credit: Ascendis Pharma AS

A recently filed patent (Publication Number: US20230414770A1) discloses a cross-linked HA drug conjugate for treating ocular indications. The conjugate comprises hyaluronic acid polymers 2A and 2B, with specific formulas for the reversible prodrug linker L2 and spacer L4 connecting the polymers. The drug in the conjugate is an antibody, particularly a VEGF antagonist like ranibizumab in the form of a Fab antibody fragment. The patent also includes a method for treating ocular indications by administering the composition intraocularly, specifically into the vitreum using a needle of specified gauge sizes.

The patent outlines a method for treating various ocular indications such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), and other related conditions. The treatment involves administering the disclosed composition, particularly for AMD, using a specific injection technique into the vitreum. The patent provides detailed information on the specific ocular indications targeted by the treatment, including neovascular diseases, retinal degeneration, and inflammatory conditions like uveitis and conjunctivitis. Overall, the patent aims to offer a novel approach to treating ocular diseases using the disclosed HA drug conjugate and administration method, focusing on improving outcomes for patients with various eye-related conditions.

To know more about GlobalData’s detailed insights on Ascendis Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies